Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Oct 26, 2020

Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

- First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
Oct 21, 2020

Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

* $1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)
Oct 20, 2020

Sanofi and Merck to present three new studies highlighting combination pediatric vaccines at IDWeek 2020
Oct 13, 2020

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
Oct 1, 2020

Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D)

- Healthcare professional and patient campaigns focus on screening for early-stage T1D-

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.